HAVCR2 and acute myeloid leukemia: Studies have found that in patients with AML, NK cells expressing TIM-3 exhibit greater responsiveness to stimulation compared to their TIM-3-negative counterparts, and such responses are partially inhibited by TIM-3 blockade.